1. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer


    Xi Su et al, 2020, OncoTargets and Therapy CrossRef
  2. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis
    Takaaki Oba et al, 2020, Endocrine Journal CrossRef
  3. A Case of Unresectable Papillary Thyroid Carcinoma Treated with Lenvatinib as Neoadjuvant Chemotherapy
    Hiroyuki Iwasaki et al, 2020, Case Reports in Endocrinology CrossRef
  4. Multimodality Treatment Improves Locoregional Control, Progression-Free and Overall Survival in Patients with Anaplastic Thyroid Cancer: A Retrospective Cohort Study Comparing Oncological Outcomes and Morbidity between Multimodality Treatment and Limited Treatment
    Pascal K. C. Jonker et al, 2021, Annals of Surgical Oncology CrossRef
  5. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
    Dongmei Huang et al, 2022, Frontiers in Endocrinology CrossRef
  6. Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer
    Hiroyuki Iwasaki et al, 2019, Molecular and Clinical Oncology CrossRef
  7. Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies
    Bo-Hua Kuang et al, 2024, Frontiers in Endocrinology CrossRef
  8. Treatment of anaplastic thyroid cancer with tyrosine kinase inhibitors targeted on the tumor vasculature: initial experience in clinical practice
    Sae Ishihara et al, 2021, Endocrine Journal CrossRef
  9. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis
    Soo Young Kim et al, 2020, Frontiers in Endocrinology CrossRef